Erin Eastern

Chief Human Capital Officer at MyClean, Inc.

Erin Eastern

Erin Eastern

Chief Human Capital Officer at MyClean, Inc.

Overview
Career Highlights

PellePharm, Inc.

RelSci Relationships

16

Relationships
RelSci Relationships are individuals Erin Eastern likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at PellePharm, Inc.

Relationship likelihood: Strong

Co-Founder & Director at PellePharm, Inc.

Relationship likelihood: Strong

Treasurer at MyoTherix, Inc.

Relationship likelihood: Strong

Co-Founder at Bridgebio Pharma LLC

Relationship likelihood: Strong

Director & Professor-Emeritus at UCSF Helen Diller Family Comprehensive Cancer Center

Relationship likelihood: Strong

Member, Board of Directors at PellePharm, Inc.

Relationship likelihood: Strong

Chief Executive Officer-in-Residence at Bridgebio Pharma LLC

Relationship likelihood: Strong

Co-Founder & Chief Operating Officer at Paintzen, Inc.

Relationship likelihood: Strong

Co-Founder & Chief Executive Officer at MyClean, Inc.

Relationship likelihood: Strong

Co-Founder at MyClean, Inc.

Relationship likelihood: Strong

Paths to Erin Eastern
Potential Connections via
Relationship Science
You
Erin Eastern
Chief Human Capital Officer at MyClean, Inc.
Career History
Chief Human Capital Officer
Current

MyClean, Inc. offers residential and commercial cleaning services. It provides cleaning services for bedrooms, living rooms, kitchen, bathrooms and common areas. The firm serves customers in the areas of home, apartment and offices. The company was founded by Jordan Saxe, Justin Geller, Michael S. Russell, Lee Finkel, and Michael D. Scharf in 2009 and is headquartered in New York, NY.

President & Director
Prior

PellePharm is developing patidegib, a novel hedgehog pathway inhibitor, to mitigate the tumor burden in patients with basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating rare genetic skin disease. The company is focused on developing and commercializing this treatment to reduce the burden of disease and improve quality of life by potentially reducing invasive and painful surgeries and the scarring that often accompanies them. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently being studied in a phase 2 clinical trial for the treatment of sporadic BCCs.

Boards & Committees
President & Director
Prior

PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. It also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA.

Other Affiliations

Erin Eastern is affiliated with MyClean, Inc., PellePharm, Inc., PellePharm, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Erin Eastern. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Erin Eastern's profile does not indicate a business or promotional relationship of any kind between RelSci and Erin Eastern.